Dmitri Wiederschain, Ph.D.
Affiliations: | 2003 | Harvard University, Cambridge, MA, United States |
Area:
Molecular BiologyGoogle:
"Dmitri Wiederschain"Parents
Sign in to add mentor| Zhi-Min Yuan | grad student | 2003 | Harvard | |
| (Molecular mechanisms of p53 functional inactivation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Greco R, Qu H, Qu H, et al. (2020) Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. Oncoimmunology. 9: 1811605 |
| Zhu C, Song Z, Wang A, et al. (2020) Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Frontiers in Immunology. 11: 1771 |
| Theilhaber J, Pollard J, Pomponio R, et al. (2020) Abstract 4321: Integrating multiplex immunohistochemistry (IHC) and transcriptomics for characterization of association between spatial heterogeneity of lymphocytic infiltration and TGFβ pathway activity in solid tumors Endocrinology. 80: 4321-4321 |
| Wagenaar TR, Hotz C, Gieseke F, et al. (2018) Abstract LB-130: Combinatorial treatment with intratumoral cytokine mRNAs results in high frequency of tumor rejection and development of anti-tumor immunity across a range of preclinical cancer models Cancer Research. 78 |
| Theilhaber J, Cavallo J, Madden SL, et al. (2018) Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy Cancer Research. 78: 5550-5550 |
| Henry C, Lampa M, He T, et al. (2018) Abstract 5472: Basal-like breast cancer subtype is characterized by deregulated glutamine metabolism and is sensitive to GLS inhibition Cancer Research. 78: 5472-5472 |
| Lampa M, Arlt H, He T, et al. (2017) Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. Plos One. 12: e0185092 |
| Tateishi K, Wakimoto H, Iafrate AJ, et al. (2015) Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 28: 773-84 |
| Deng G, Shen J, Yin M, et al. (2015) Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. The Journal of Biological Chemistry. 290: 762-74 |
| Huang SM, Wang A, Greco R, et al. (2014) Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. Oncotarget. 5: 3362-74 |